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Abstract
We investigated the effects of DHEA and DHEA-S on glucose metabolism using 
diabetic mice db/db in vivo. The DHEA-S-treated mice showed more prominent 
hepatomegaly and a greater decrease of the serum glucose level than DHEA-treated 
mice. These preliminary data suggest that DHEA-S has a stronger hypoglycemic 
effect than DHEA, or even that the hypoglycemic effect may be due to DHEA-S, 
rather than DHEA. The modes of action of DHEA and DHEA-S in diabetic mice 
should be evaluated from the perspective that these steroids have distinct effects, 
that can contribute to clarifying the basic pathogenesis of diabetes mellitus.
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Introduction
 Dehydroepiandrosterone (DHEA) and DHEA 
sulfate (DHEA-S) are adrenal androgens, 
DHEA-S being the most abundant adrenal 
steroid in humans. Serum levels of DHEA 
range from 7 to  31 nmol/L, whereas DHEA-S 
levels range from 2 to 10  ,urnol/L in men (Orth 
DN et al., 1992). These androgens show 
increased serum levels at puberty, reach their 
highest levels in the second decade of life and 
decrease with senescence. Based on these 
changes, there is a physiological significance 
associated with aging, and possible effects on
aging-related diseases have been investigated 
but there are no reports showing clear data on 
their effects on aging and aging-related 
diseases such as diabetes mellitus in humans. 
 Using rodents, which secrete little or no 
DHEA and DHEA-S from their adrenal glands, 
Coleman et al. first showed the potential 
therapeutic value of DHEA on diabetes 
mellitus (1982). They demonstrated that 
DHEA causes rapid remission of hyper-
glycemia and the preservation of islet cells in 
genetically diabetic mice (db/db). Aoki and 
Sekihara suggested that suppression of 
elevated activity of hepatic gluconeogenic
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enzymes, such as glucose-6-phosphatase, may 
lead to decreased glucose production in db/db 
mice (1999). 
 As the metabolism of three steroids and 
glucose in humans is different from that in 
mice, the proven effects of DHEA and DHEA-S 
on hyperglycemia in mice cannot be extra-
polated to humans directly. However, invest-
igating the role of these steroids on glucose 
metabolism in vivo is valuable to elucidate the 
basic pathogenesis of diabetes mellitus. 
 Previously we observed hepatomegaly with 
peroxisome proliferation in normal mice 
treated with DHEA or DHEA-S. The oral 
administration of DHEA or DHEA-S activated 
the constitutive androstane receptor   (CAR  ) 
and induced the expression of  Cyp2b10, a 
target gene of CAR , in the liver. However, 
there was a difference in the degree of 
 Cyp2b10 expression between DHEA-treated 
mice and DHEA-S-treated mice (Fujita et al., 
2002). 
 Ultimately the mechanism of the effects of 
DHEA and DHEA-S on hyperglycemia is not 
completely understood, and the effects of 
DHEA and DHEA-S have not yet been 
compared. Here we report the preliminary 
results of our investigation into differences in 
the effects of DHEA and DHEA-S in vivo using 
type 2 diabetic (db/db) mice.
Materials  and  methods
 Fourteen-week-old male diabetic mice of C 
57BL/ksj db/db were obtained from CLEA 
Japan (Tokyo, Japan). Two or three mice were 
placed in one cage in a temperature-regulated 
 (25 ±1°C) and humidity-controlled (55%) room 
with a 12-h  light/12-h dark cycle and barrier 
against pathogens. Water and food (Oriental 
MF, Oriental, Tokyo, Japan) were available ad 
libitum throughout the experimental period. 
At  16 weeks of age, the mice were divided into 
three groups  (n = 6) and fed with control 
(standard pellet food), DHEA-containing or
Table 1
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DHEA-S-containing diet. DHEA or DHEA-S, 
obtained from Sigma Chemical Co. (St. Louis, 
MO, USA), was mixed with standard food 
powder and pelleted by Oriental Co. Ltd. 
(Tokyo, Japan) at a final concentration of 0.4% 
(w/w). The diets were weighed to determine 
the amount of food eaten each day. 
Wholebody weights and serum glucose levels 
of the mice were measured before and after 
two weeks of feeding. Serum glucose levels 
were estimated using a portable glucose 
meter (Glutest, Sanwa Kagaku Kenkyusho 
Co., Ltd., Nagoya, Japan) in peripheral 
blood from the tail vein after a one-night 
fast. On day 16, after glucose measurements 
were taken, the mice were sacrificed by 
cervical dislocation and the livers and 
periepididymal adipose tissues were removed 
and weighed. 
 All animal studies were performed after 
obtaining the approval of Osaka Medical 
College Animal Care and Use Committee.
 Results
 Body weights and food intake after the 
DHEA and DHEA-S treatments are shown in 
Table 1. The DHEA-treated db/db mice ate 
less than the other groups, but their body 
weight had not changed significantly by the 
end of either DHEA or DHEA-S treatment. 
 The DHEA- and DHEA-S-treated db/db mice 
showed hepatomegaly (Fig.  1A) and their liver 
weight increased significantly but there was 
no significant difference in periepididymal 
adipose tissue after the treatment (Fig.  1B). 
 The serum glucose level showed a decrease 
in both the DHEA and DHEA-S groups, and 
the DHEA-S group showed a greater decrease 
than DHEA group although there was no 
significant change between these two groups 
in day 14 (Fig. 2).
The whole body weight and average amount of food eaten each day per 
head (g) in control, DHEA-treated and DHEA-S treated mice (mean ± 
SD). Statistical analysis was performed by One-way ANOVA  /Turkey's 
honestly significant difference test. ( : significant)
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Discussion
Fig. 1 Change of the liver after the treatments 
The autopsy showed the hepatomegaly of the  DHEA- and DHEA-S-treated 
 db/db mice (A). The  liver weights increased  in both the treated groups but 
there was no difference among the periepididymal adipose tissues (B). 
Statistical analysis was performed by One-way ANOVA/Tukey's honestly 
significant difference test (t: significant).
 Since Coleman et al. reported the  hypo-
glycemic effect of DHEA in db/db mice (1982), 
several investigators have reported the 
mechanisms of DHEA and DHEA-S (Aoki et al., 
1999; Dillon JS et al., 2000; Medina MC et al., 
2006). However, none of these studies dis-
cussed differences in the effects of DHEA and 
DHEA-S. It is difficult to distinguish their 
pharmacological mechanisms because DHEA 
can easily be converted to DHEA-S and vice 
versa in vivo. 
 To clarify the modes of action, we compared 
the effects of DHEA and DHEA-S in db/db 
mice and demonstrated differences in liver 
weights and serum glucose levels between the 
two groups.
 Although the DHEA-treated mice ate rela-
tively less food than the other groups, there 
was no significant effect on body weight 
(Table 1). This is likely due to either the 
relatively brief (two-week) length of the 
experiment or to differences in metabolism. 
The greater body-weight gain in DHEA-S-
treated mice can be considered a result of liver 
enlargement (Fig. 1). 
 Hepatomegaly associated with peroxisome 
proliferation was also more prominent in 
DHEA-S-treated normal mice than in DHEA-
treated normal mice (Fujita et al., 2002). 
 As DHEA-S is reported to stimulate per-
oxisome proliferator activated receptor alpha 
(PPARa) in the liver (Peters JM et al.,  1996), our 
findings further suggest that hepatomegaly in 
db/db mice may be caused by the action of
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Fig. 2 Serum glucose levels after DHEA or  DHEA-S 
treatments in db/db mice. 
The serum glucose levels decreased in both the 
DHEA and  DHEA-S mice, but the  DHEA-S mice 
showed a greater decrease. 
 **:  P  <  0.01,  *:P  <  0.05: Paired t-test, t: one-way 
ANOVA/Tukey's honestly significant difference 
test.
DHEA-S, rather than by DHEA. 
 In the previous study, we also demonstrated 
that  Cyp2b10 expression showed a correlation 
with DHEA-S in DHEA-treated mice, but an 
inverse correlation in DHEA-S-treated mice. 
 The degree of decrease in serum glucose 
levels was larger in the DHEA-S-treated group 
than in the DHEA-treated group (Fig. 2). The 
concentrations of both DHEA and DHEA-S 
were elevated in each treatment group, 
although the amount of DHEA-S found in the 
DHEA-S-treated group was more than twice 
the amount found in the DHEA-treated group 
in normal mice (Fujita et al., 2002). The fact 
that serum glucose levels decreased in 
proportion to the concentration of serum 
DHEA-S suggests that DHEA-S has a stronger
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hypoglycemic effect than DHEA, or even that 
the hypoglycemic effect may be due to 
DHEA-S, rather than DHEA. 
 We suppose that the pharmacological 
mechanism might differ between these two 
chemical structures, and that evaluating 
differences in their effects in vivo is important 
to clarify their roles in glucose metabolism.
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